These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 36908315)

  • 1. Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis.
    Pei WG; Chen WZ; Wu YK; Tan SX; Jie ZG
    World J Gastrointest Oncol; 2023 Feb; 15(2):352-367. PubMed ID: 36908315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
    Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.
    Wang BC; Zhang ZJ; Fu C; Wang C
    Medicine (Baltimore); 2019 Nov; 98(47):e18054. PubMed ID: 31764833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
    Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
    EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
    Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
    Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.
    Wang PF; Chen Y; Song SY; Wang TJ; Ji WJ; Li SW; Liu N; Yan CX
    Front Pharmacol; 2017; 8():730. PubMed ID: 29093678
    [No Abstract]   [Full Text] [Related]  

  • 12. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis.
    Zhao P; Zhao T; Yu L; Ma W; Liu W; Zhang C
    Front Oncol; 2024; 14():1381250. PubMed ID: 38756658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
    Yuan Z; Cui H; Wang S; Liang W; Cao B; Song L; Liu G; Huang J; Chen L; Wei B
    Front Oncol; 2023; 13():1103320. PubMed ID: 36776290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of endocrine-related immune-related adverse events in Japanese subjects with various types of cancer.
    Iwamoto Y; Kimura T; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    Front Endocrinol (Lausanne); 2023; 14():1079074. PubMed ID: 36755909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
    Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
    Front Oncol; 2022; 12():976224. PubMed ID: 36185176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
    Huang Y; Ma W; Wu D; Lyu M; Zheng Q; Wang T; Zhou J; Liu C
    Transl Lung Cancer Res; 2024 Jul; 13(7):1559-1584. PubMed ID: 39118883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.